Expression and prognostic significance of MAP4K4 in lung adenocarcinoma

Pathology Research and Practice

Volumn 208, Issue 9, 2012, Pages 541-548

  Qiu, Mei Hua ^a   Qian, Yi Ming ^b   Zhao, Xiang Li ^b   Wang, Shou Mei ^b   Feng, Xiao Jun ^b   Chen, Xin Fang ^c   Zhang, Shu Hui ^b  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Immunohistochemistry; Lung adenocarcinoma; MAP4K4; Prognostic factor

Indexed keywords

MITOGEN ACTIVATED PROTEIN 4 KINASE 4; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PLEURA; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOCARCINOMA; BLOTTING, WESTERN; CHINA; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PLEURA; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 84865296967     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2012.06.001     Document Type: Article

References (25)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Fritz P., Coy J.F., Murdter T.E., Ott G., Alscher M.D., Friedel G. TKTL-1 expression in lung cancer. Pathol. Res. Pract. 2012, 208:203-209.
3. Haruki T., Shomori K., Hamamoto Y., Taniguchi Y., Nakamura H., Ito H. Geminin expression in small lung adenocarcinomas: implication of prognostic significance. Lung Cancer 2011, 71:356-362.
4. Kato T., Daigo Y., Aragaki M., Ishikawa K., Sato M., Kondo S., Kaji M. Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients. Lung Cancer 2011, 74:124-131.
5. Yatabe Y., Borczuk A.C., Powell C.A. Do all lung adenocarcinomas follow a stepwise progression?. Lung Cancer 2011, 74:7-11.
6. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., Beer D.G., Powell C.A., Riely G.J., Van Schil P.E., Garg K., Austin J.H., Asamura H., Rusch V.W., Hirsch F.R., Scagliotti G., Mitsudomi T., Huber R.M., Ishikawa Y., Jett J., Sanchez-Cespedes M., Sculier J.P., Takahashi T., Tsuboi M., Vansteenkiste J., Wistuba I., Yang P.C., Aberle D., Brambilla C., Flieder D., Franklin W., Gazdar A., Gould M., Hasleton P., Henderson D., Johnson B., Johnson D., Kerr K., Kuriyama K., Lee J.S., Miller V.A., Petersen I., Roggli V., Rosell R., Saijo N., Thunnissen E., Tsao M., Yankelewitz D. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 2011, 6:244-285.
7. Russell P.A., Wainer Z., Wright G.M., Daniels M., Conron M., Williams R.A. Does lung adenocarcinoma subtype predict patient survival?: a clinicopathologic study based on the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary lung adenocarcinoma classification. J. Thorac. Oncol. 2011, 6:1496-1504.
8. Collins C.S., Hong J., Sapinoso L., Zhou Y., Liu Z., Micklash K., Schultz P.G., Hampton G.M. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:3775-3780.
9. Liu A.W., Cai J., Zhao X.L., Jiang T.H., He T.F., Fu H.Q., Zhu M.H., Zhang S.H. ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin. Cancer Res. 2011, 17:710-720.
10. Liang J.J., Wang H., Rashid A., Tan T.H., Hwang R.F., Hamilton S.R., Abbruzzese J.L., Evans D.B., Wang H. Expression of MAP4K4 is associated with worse prognosis in patients with stage II pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2008, 14:7043-7049.
11. Sobin L., Gospodarowicz M., Wittekind C. TNM Classification of Malignant Tumours 2009, Wiley-Liss Inc., New York, pp. 138-146. 7th ed.
12. Liao W.T., Wang X., Xu L.H., Kong Q.L., Yu C.P., Li M.Z., Shi L., Zeng M.S., Song L.B. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival. Cancer 2009, 115:1507-1517.
13. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
14. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
15. Zhu Z., Luo Z., Li Y., Ni C., Li H., Zhu M. Human inhibitor of growth 1 inhibits hepatoma cell growth and influences p53 stability in a variant-dependent manner. Hepatology 2009, 49:504-512.
16. Kononen J., Bubendorf L., Kallioniemi A., Barlund M., Schraml P., Leighton S., Torhorst J., Mihatsch M.J., Sauter G., Kallioniemi O.P. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 1998, 4:844-847.
17. Han S.X., Zhu Q., Ma J.L., Zhao J., Huang C., Jia X., Zhang D. Lowered HGK expression inhibits cell invasion and adhesion in hepatocellular carcinoma cell line HepG2. World J. Gastroenterol. 2010, 16:4541-4548.
18. Bonanno L., Schiavon M., Nardo G., Bertorelle R., Bonaldi L., Galligioni A., Indraccolo S., Pasello G., Rea F., Favaretto A. Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma. Anticancer Res. 2011, 30:5121-5128.
19. Tanaka A., Sueoka-Aragane N., Nakamura T., Takeda Y., Mitsuoka M., Yamasaki F., Hayashi S., Sueoka E., Kimura S. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. Lung Cancer 2012, 75:89-94.
20. Chiosea S.I., Sherer C.K., Jelic T., Dacic S. KRAS mutant allele-specific imbalance in lung adenocarcinoma. Mod. Pathol. 2011, 24:1571-1577.
21. Fassan M., Rea F., Pizzi M., Rugge M. HER-2/neu expression is consistent in primary and metastatic lung adenocarcinoma. Lung Cancer 2011, 71:371-372.
22. Hiramatsu M., Ninomiya H., Inamura K., Nomura K., Takeuchi K., Satoh Y., Okumura S., Nakagawa K., Yamori T., Matsuura M., Morikawa T., Ishikawa Y. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. Lung Cancer 2010, 70:94-102.
23. Lee J.G., Kim S., Shim H.S. Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung. Lung Cancer 2012, 77:156-161.
24. Matsubara D., Morikawa T., Goto A., Nakajima J., Fukayama M., Niki T. Subepithelial myofibroblast in lung adenocarcinoma: a histological indicator of excellent prognosis. Mod. Pathol. 2009, 22:776-785.
25. MacDermed D.M., Khodarev N.N., Pitroda S.P., Edwards D.C., Pelizzari C.A., Huang L., Kufe D.W., Weichselbaum R.R. MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med. Genomics 2010, 3:16.